Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 28, 2025

Grab's Super-App Is Working, But the Market Isn't Fully Pricing It In

View original at finance.yahoo.com
Grab's Super-App Is Working, But the Market Isn't Fully Pricing It In This article first appeared on GuruFocus. Grab Holdings (NASDAQ:GRAB) has continued its steady march toward profitability, as evidenced by a profitable third quarter of 2025 and raised full-year guidance…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The loan portfolio generates healthy risk-adjusted returns above the cost of capital

    80% confidence
  • 90% of new bank customers for GXBank in Malaysia were acquired at essentially zero cost through the Grab app's existing user base

    80% confidence
  • Management proactively adjusted deposit rates to manage funding costs in line with market rates

    80% confidence
  • 90-day non-performing loans are within risk appetite

    80% confidence
  • Approximately one-third of customers accessing Grab's credit products were previously unable to obtain credit due to a lack of a credit bureau record

    80% confidence
  • Multi-service users spend 4x more and transact twice as often as single-service users

    80% confidence
  • The Indonesian government is backing the potential M&A between Grab and GoTo

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com